1.Chen Q, Zeng X, Huang D, Qiu X. Identification of differentially expressed miRNAs in early-stage cervical cancer with lymph node metastasis across The Cancer Genome Atlas datasets. nCancer management and research. 2018;10:6489.
2.Parkin DM, Bray F. The burden of HPV-related cancers. Vaccine. 2006;24:S11-S25.
3.Patel S, Chiplunkar S. Host immune responses to cervical cancer. Current Opinion in Obstetrics and Gynecology. 2009;21(1):54–59.
4.Roden R, Wu T-C. How will HPV vaccines affect cervical cancer? Nature Reviews Cancer. 2006;6(10):753.
5.Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. American journal of epidemiology. 2008;168(2):123–137.
6.Small Jr W, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, et al. Cervical cancer: a global health crisis. Cancer. 2017;123(13):2404–2412.
7.Korn T, Bettelli E, Oukka M, Kuchroo VK. IL–17 and Th17 Cells. Annual review of immunology. 2009;27:485–517.
8.Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL–17+ T helper cells. Cell. 2006;126(6):1121–1133.
9.Xie J, Wang J, Tang T, Chen J, Gao X, Yuan J, et al. The Th17/Treg functional imbalance during atherogenesis in ApoE−/− mice. Cytokine. 2010;49(2):185–193.
10.Zhu X, Ma D, Zhang J, Peng J, Qu X, Ji C, et al. Elevated interleukin–21 correlated to Th17 and Th1 cells in patients with immune thrombocytopenia. Journal of clinical immunology. 2010;30(2):253–259.
11.Bettelli E, Oukka M, Kuchroo VK. T H–17 cells in the circle of immunity and autoimmunity. Nature immunology. 2007;8(4):345.
12.Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson CC. Regulatory T cells in cancer. Advances in cancer research. 107: Elsevier; 2010. p. 57–117.
13.Wang R, editor Regulatory T cells and innate immune regulation in tumor immunity. Springer seminars in immunopathology; 2006: Springer.
14.Kieler M, Unseld M, Bianconi D, Prager G. Challenges and perspectives for immunotherapy in adenocarcinoma of the pancreas: the cancer immunity cycle. Pancreas. 2018;47(2):142–157.
15.Hwang JP, Ahmed S, Ariza-Heredia EJ, Duan Z, Zhao H, Schmeler KM, et al. Low rate of cervical cancer screening among women with hematologic malignancies after stem cell transplant. Biology of Blood and Marrow Transplantation. 2018;24(5):1094–1098.
16.Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. The Journal of pathology. 1999;189(1):12–19.
17.Fridman WH. From Cancer Immune Surveillance to Cancer Immunoediting: Birth of Modern Immuno-Oncology. The Journal of Immunology. 2018;201(3):825–826.
18.Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature medicine. 2004;10(9):942.
19.Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells. Immunological reviews. 2008;222(1):162–179.
20.Nakamura T, Shima T, Saeki A, Hidaka T, Nakashima A, Takikawa O, et al. Expression of indoleamine 2, 3‐dioxygenase and the recruitment of Foxp3‐expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer science. 2007;98(6):874–881.
21.Takakura M, Matsumoto T, Nakamura M, Mizumoto Y, Myojyo S, Yamazaki R, et al. Detection of circulating tumor cells in cervical cancer using a conditionally replicative adenovirus targeting telomerase‐positive cells. Cancer science. 2018;109(1):231–240.
22.Zhang B, Rong G, Wei H, Zhang M, Bi J, Ma L, et al. The prevalence of Th17 cells in patients with gastric cancer. Biochemical and biophysical research communications. 2008;374(3):533–537.
23.Miller AM, Lundberg K, Özenci V, Banham AH, Hellström M, Egevad L, et al. CD4+ CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. The Journal of Immunology. 2006;177(10):7398–7405.
24.Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, Kolls J, et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL–2 in the tumor microenvironment. The Journal of Immunology. 2007;178(11):6730–6733.
25.Bais AG, Beckmann I, Ewing PC, Eijkemans MJ, Meijer CJ, Snijders PJ, et al. Cytokine Release in HR-HPV. Mediators of inflammation. 2007;2007.